Discovering New Acetylcholinesterase Inhibitors by Mining the Buzhongyiqi Decoction Recipe Data

Myasthenia gravis (MG) is a neuromuscular disease that is conventionally treated with acetylcholinesterase (AChE) inhibitors, which may not fully remove the symptom for many reasons. When AChE inhibitors do not work, Chinese patients turn to Chinese medicine, such as the Buzhongyiqi decoction (BD), to treat MG. By elucidating the relations between the herbs of the Buzhongyiqi decoction recipe and AChE inhibitors with structure-based and ligand-based drug design methods and chemoinformatics approaches, we have found the key active components of BD. Using these key active components as templates, we have discovered five new AChE inhibitors through virtual screening of a commercial compound library. The new AChE inhibitors have been confirmed with Ellman assays. This study demonstrates that lead identification can be inspired by elucidating Chinese medicine. Since BD is a mixture, further studies against other drug targets are needed.

[1]  Holger Gohlke,et al.  MMPBSA.py: An Efficient Program for End-State Free Energy Calculations. , 2012, Journal of chemical theory and computation.

[2]  Sorel Muresan,et al.  Developing a drug-like natural product library. , 2008, Journal of natural products.

[3]  Lorenzo Maggi,et al.  Treatment of Myasthenia Gravis , 2011, Clinical drug investigation.

[4]  E. Giacobini,et al.  Cholinesterase inhibitors: new roles and therapeutic alternatives. , 2004, Pharmacological research.

[5]  Junmei Wang,et al.  Development and testing of a general amber force field , 2004, J. Comput. Chem..

[6]  Xin Yan,et al.  LBVS: an online platform for ligand-based virtual screening using publicly accessible databases , 2014, Molecular Diversity.

[7]  I. Kola,et al.  Can the pharmaceutical industry reduce attrition rates? , 2004, Nature Reviews Drug Discovery.

[8]  Trevor Hughes,et al.  The early history of myasthenia gravis , 2005, Neuromuscular Disorders.

[9]  Xue Xu,et al.  A System-Level Investigation into the Mechanisms of Chinese Traditional Medicine: Compound Danshen Formula for Cardiovascular Disease Treatment , 2012, PloS one.

[10]  K. Courtney,et al.  A new and rapid colorimetric determination of acetylcholinesterase activity. , 1961, Biochemical pharmacology.

[11]  Bruno Eymard,et al.  Diagnostic and clinical classification of autoimmune myasthenia gravis. , 2014, Journal of autoimmunity.

[12]  G. Ciccotti,et al.  Numerical Integration of the Cartesian Equations of Motion of a System with Constraints: Molecular Dynamics of n-Alkanes , 1977 .

[13]  G. Klebe Virtual ligand screening: strategies, perspectives and limitations , 2006, Drug Discovery Today.

[14]  Nils Erik Gilhus,et al.  Myasthenia Gravis: A Review of Available Treatment Approaches , 2011, Autoimmune diseases.

[15]  Monica Milani,et al.  Myasthenia gravis: past, present, and future. , 2006, The Journal of clinical investigation.

[16]  D. Normile The New Face of Traditional Chinese Medicine , 2003, Science.

[17]  Yang Sun,et al.  Synthesis and evaluation of multi-target-directed ligands against Alzheimer's disease based on the fusion of donepezil and ebselen. , 2013, Journal of medicinal chemistry.

[18]  Ping Liu,et al.  Clinical treatment of myasthenia gravis with deficiency of spleen and kidney based on combination of disease with syndrome theory. , 2013, Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan.

[19]  Wei Zhou,et al.  TCMSP: a database of systems pharmacology for drug discovery from herbal medicines , 2014, Journal of Cheminformatics.

[20]  Dennis Normile,et al.  Asian medicine. The new face of traditional Chinese medicine. , 2003, Science.

[21]  Xin Yan,et al.  GSA: a GPU-accelerated structure similarity algorithm and its application in progressive virtual screening , 2012, Molecular Diversity.

[22]  Holger Gohlke,et al.  The Amber biomolecular simulation programs , 2005, J. Comput. Chem..

[23]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. , 2001, Advanced drug delivery reviews.

[24]  M. Kurukumbi,et al.  Myasthenia Gravis: A Review , 2012, Autoimmune diseases.

[25]  Wolfgang Sippl,et al.  Molecular Modeling of Potential Anticancer Agents from African Medicinal Plants , 2014, J. Chem. Inf. Model..

[26]  V. Hornak,et al.  Comparison of multiple Amber force fields and development of improved protein backbone parameters , 2006, Proteins.

[27]  John C. Keesey,et al.  Clinical evaluation and management of myasthenia gravis , 2004, Muscle & nerve.

[28]  A Szobor,et al.  On the treatment of myasthenia gravis. , 1969, Acta medica Academiae Scientiarum Hungaricae.

[29]  H. Kaminski,et al.  Treatment of Myasthenia Gravis , 2011, Current neurology and neuroscience reports.

[30]  Minghao Zheng,et al.  Enhancing Molecular Shape Comparison by Weighted Gaussian Functions , 2013, J. Chem. Inf. Model..

[31]  Ruibo Wu,et al.  Molecular Dynamics-Based Virtual Screening: Accelerating the Drug Discovery Process by High-Performance Computing , 2013, J. Chem. Inf. Model..

[32]  Jun Xu A new approach to finding natural chemical structure classes. , 2002, Journal of medicinal chemistry.

[33]  Xin Yan,et al.  gWEGA: GPU‐accelerated WEGA for molecular superposition and shape comparison , 2014, J. Comput. Chem..

[34]  P. Williams,et al.  Natural products as a source of Alzheimer's drug leads. , 2011, Natural product reports.

[35]  S. Berrih-Aknin,et al.  Myasthenia gravis: a comprehensive review of immune dysregulation and etiological mechanisms. , 2014, Journal of autoimmunity.

[36]  P. Kollman,et al.  Automatic atom type and bond type perception in molecular mechanical calculations. , 2006, Journal of molecular graphics & modelling.

[37]  Xin Yan,et al.  Big data in drug design , 2015 .

[38]  Peng Jiang,et al.  Molecular networks for the study of TCM Pharmacology , 2010, Briefings Bioinform..

[39]  F. Schumm,et al.  Symptomatische Therapie bei Myasthenia gravis und anderen neuromuskulären Übertragungsstörungen , 2011 .

[40]  Mankil Jung,et al.  Acetylcholinesterase inhibition by flavonoids from Agrimonia pilosa. , 2007, Molecules.

[41]  Abdul Malik,et al.  Cholinesterase Inhibitory Constituents from Onosma hispida. , 2003 .

[42]  J. Pearce,et al.  Mary Broadfoot Walker (1888–1974): A Historic Discovery in Myasthenia gravis , 2004, European Neurology.

[43]  M. Rudolph,et al.  Structures of human acetylcholinesterase in complex with pharmacologically important ligands. , 2012, Journal of medicinal chemistry.